The Sovaldi Anniversary? Burgess Wants Part D Milestone To Change How Gov’t Values Rx Spending
Executive Summary
Congressional budget projections should use longer time horizons, Vice-Chair of House Energy and Commerce Health Subcommittee argues; meanwhile former FDA Commissioner suggests costly drugs could be paid for on a mortgage model.
You may also be interested in...
Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs
Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.
Drug Approval Reforms Ineffective Without Payer Reforms, Tunis Argues
Granting payers more conditional coverage authority may be necessary for legislation to succeed at accelerating biomedical innovation, the former CMS CMO argues, but industry may not be on board.
CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs
In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.